Investigational Drug Information for Tegafur
✉ Email this page to a colleague
What is the development status for investigational drug Tegafur?
Tegafur is an investigational drug.
There have been 152 clinical trials for Tegafur.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Cancer Institute (NCI).
There are eight hundred and twenty-eight US patents protecting this investigational drug and sixteen international patents.
Summary for Tegafur
| US Patents | 828 |
| International Patents | 16,975 |
| US Patent Applications | 6,556 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 438 |
| Clinical Trial Progress | Phase 3 (2014-09-01) |
| Vendors | 93 |
Recent Clinical Trials for Tegafur
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Chugai Pharmaceutical Co. | Phase 1 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Genentech, Inc. | Phase 1 |
| An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC | Xijing Hospital | N/A |
Clinical Trial Summary for Tegafur
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
US Patents for Tegafur
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegafur | ⤷ Try a Trial | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | ⤷ Try a Trial |
| Tegafur | ⤷ Try a Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Try a Trial |
| Tegafur | ⤷ Try a Trial | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same | Protalix Ltd. (Carmiel, IL) | ⤷ Try a Trial |
| Tegafur | ⤷ Try a Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Try a Trial |
| Tegafur | ⤷ Try a Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegafur
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegafur | Australia | AU2014232383 | 2033-03-15 | ⤷ Try a Trial |
| Tegafur | Australia | AU2019202731 | 2033-03-15 | ⤷ Try a Trial |
| Tegafur | Australia | AU2019288275 | 2033-03-15 | ⤷ Try a Trial |
| Tegafur | Brazil | BR112015023267 | 2033-03-15 | ⤷ Try a Trial |
| Tegafur | Brazil | BR112020025927 | 2033-03-15 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
